Keyphrases
Tumor Necrosis Factor-α
80%
Erectile
80%
Erectile Dysfunction
70%
Specific Intent
20%
Cardiovascular Disease
20%
Erectile Function
19%
Inflammatory Cytokines
12%
Contractile Response
10%
Hypertension
8%
Cavernosal Smooth muscle
8%
Smooth muscle Cells
8%
Public Health Risk
7%
Therapeutic Potential
7%
PDE5 Inhibitors
7%
Patients with Cardiovascular Diseases
7%
Penile Function
6%
NO Bioavailability
5%
Vascular Changes
5%
Population Aging
5%
Vascular Bed
5%
Disease Treatment
5%
Vascular Function
5%
Endothelin-1 (ET-1)
5%
Constrictor
5%
Clinical Trials
5%
Obesity
5%
Specific Mechanisms
5%
Vascular Dysfunction
5%
RhoA
5%
Clinical Manifestations
5%
Metabolic Disorders
5%
Cardiovascular Events
5%
Vascular Disease
5%
Medicine and Dentistry
Tumor Necrosis Factor
100%
Erectile Dysfunction
85%
Cardiovascular Disease
32%
Inflammatory Cytokine
15%
Smooth Muscle Cell
10%
Drug Therapy
9%
Disease
9%
Phosphodiesterase V Inhibitor
9%
Public Health
9%
Bioavailability
6%
Cardiovascular System
6%
Water-Electrolyte Imbalance
6%
Combination Therapy
6%
Sodium Chloride
6%
Clinical Research
6%
Vascular Disease
6%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Erectile Dysfunction
85%
Cardiovascular Disease
32%
Cytokine
20%
Phosphodiesterase V Inhibitor
9%
Disease
9%
Metabolic Disorder
6%
Combination Therapy
6%
Sodium Chloride
6%
Vascular Disease
6%
Clinical Research
6%
Bioavailability
6%